ALK and adenocarcinoma: Patients with EML4-ALK fusion and other ALK rearrangements represent 3–7% of all NSCLC cases, usually associated with younger age, never smoking or light smoking history and adenocarcinoma histology (especially in those tumours harbouring signet-ring cell features) [1, 2].